Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology, ISSN: 0344-5704, Vol: 34, Issue: 5, Page: 444-446
1994
- 4Citations
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
A total of 43 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a novel nitrosourea, fotemustine, given at 100 mg/m on days 1 and 8. Maintenance treatment consisted of a single injection of 100 mg/m given every 21 days. 37 patients were evaluable for respone. Of these, 5 patients had a partial response (13.5%; 95% confidence interval, 6%-28%). Toxicity comprised mainly anaemia and thrombocytopenia. Other toxicities were mild. This phase II study confirms that fotemustine is a moderately active and well-tolerated drug in NSCLC. © 1994 Springer-Verlag.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84901969785&origin=inward; http://dx.doi.org/10.1007/bf00685572; http://www.ncbi.nlm.nih.gov/pubmed/8070014; http://www.springerlink.com/Index/10.1007/s002800050169; http://dx.doi.org/10.1007/s002800050169; http://link.springer.com/10.1007/BF00685572; https://dx.doi.org/10.1007/s002800050169; https://link.springer.com/article/10.1007/BF00685572; http://www.springerlink.com/index/10.1007/BF00685572; http://www.springerlink.com/index/pdf/10.1007/BF00685572; https://dx.doi.org/10.1007/bf00685572
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know